Treatment and outcomes
| . | Non-emi group (n = 12) . | Emi group (n = 7) . | P value . |
|---|---|---|---|
| IST | |||
| PSL alone, n (%) | 9 (75) | 4 (57) | .617 |
| PSL, CyA, n (%) | 1 (8) | 0 (0) | |
| PSL, CY, n (%) | 2 (17) | 0 (0) | |
| PSL, RTX, n (%) | 0 (0) | 2 (29) | |
| PSL, CyA, RTX, n (%) | 0 (0) | 1 (14) | |
| Time from diagnosis to IST initiation, median (range), d | 1.5 (0-22) | 0 (0-14) | .047 |
| Response | |||
| PR | |||
| Patients, n (%) | 8 (67) | 5 (71) | 1.00 |
| Times from IST initiation, median (range), d | 57 (38-90) | 43 (8-85) | .222 |
| CR | |||
| Patients, n (%) | 6 (50) | 4 (57) | 1.00 |
| Times from IST initiation, median (range), d | 98.5 (69-156) | 118 (51-172) | .762 |
| Bleeding after IST initiation | |||
| Patients, n (%) | 8 (67) | 4 (57) | 1.00 |
| Total bleeding event, n | 27 | 6 | .030 |
| Severe bleeding after IST initiation | |||
| Patients, n (%) | 7 (58) | 1 (14) | .147 |
| Total severe bleeding events, n | 25 | 1 | .440 |
| Ratio of severe bleeding to all bleedings, % | 93 | 17 | |
| BPA | |||
| Patients, n (%) | 7 (58) | 2 (29) | .074 |
| Doses of BPA, median (range) | 38 (1-242) | 24.5 (19-30) | |
| Doses per patients | 43.4 | 7 | |
| Time from diagnosis to BPA initiation, median (range), d | 9 (0-35) | 0 (0-0) | .047 |
| RBC transfusions | |||
| Patients, n (%) | 11 (92) | 2 (29) | .010 |
| Units of RBC, median (range), doses | 22 (2-82) | 14 (10-18) | |
| Units per patients | 26.7 | 4 | |
| Invasive procedure | |||
| Patients, n (%) | 5 (42) | 1 (14) | .333 |
| Colonoscopy | |||
| Patients, n (%) | 5 (42) | 1 (14) | |
| Events, n | 12 | 2 | |
| Interventional radiology | |||
| Patients, n (%) | 2 (17) | 0 (0) | |
| Events, n | 4 | 0 | |
| Surgical operation | |||
| Patients, n (%) | 1 (8) | 0 (0) | |
| Events, n | 1 | 0 | |
| Cystoscopy | |||
| Patients, n (%) | 1 (8) | 0 (0) | |
| Events, n | 1 | 0 | |
| Complications | |||
| Infection | |||
| Patients, n (%) | 7 (58) | 0 (0) | .017 |
| Events, n | 13 | 0 | |
| Thrombosis | |||
| Patients, n (%) | 0 (0) | 0 (0) | |
| Events, n | 0 | 0 | |
| Hospital stays, median (range), d | 73.5 (29-202) | 44 (15-83) | <.001 |
| Outcome, n (%) | |||
| Death | 8 (67) | 0 (0) | .013 |
| During hospitalization | 3 (25) | 0 (0) | |
| After discharge | 5 (42) | 0 (0) | |
| Bleeding | 3 (25) | 0 (0) | |
| Infection | 1 (8) | 0 (0) | |
| Discharge to home | 3 (25) | 7 (100) | .003 |
| Transfer to another facilities | 6 (50) | 0 (0) | .044 |
| . | Non-emi group (n = 12) . | Emi group (n = 7) . | P value . |
|---|---|---|---|
| IST | |||
| PSL alone, n (%) | 9 (75) | 4 (57) | .617 |
| PSL, CyA, n (%) | 1 (8) | 0 (0) | |
| PSL, CY, n (%) | 2 (17) | 0 (0) | |
| PSL, RTX, n (%) | 0 (0) | 2 (29) | |
| PSL, CyA, RTX, n (%) | 0 (0) | 1 (14) | |
| Time from diagnosis to IST initiation, median (range), d | 1.5 (0-22) | 0 (0-14) | .047 |
| Response | |||
| PR | |||
| Patients, n (%) | 8 (67) | 5 (71) | 1.00 |
| Times from IST initiation, median (range), d | 57 (38-90) | 43 (8-85) | .222 |
| CR | |||
| Patients, n (%) | 6 (50) | 4 (57) | 1.00 |
| Times from IST initiation, median (range), d | 98.5 (69-156) | 118 (51-172) | .762 |
| Bleeding after IST initiation | |||
| Patients, n (%) | 8 (67) | 4 (57) | 1.00 |
| Total bleeding event, n | 27 | 6 | .030 |
| Severe bleeding after IST initiation | |||
| Patients, n (%) | 7 (58) | 1 (14) | .147 |
| Total severe bleeding events, n | 25 | 1 | .440 |
| Ratio of severe bleeding to all bleedings, % | 93 | 17 | |
| BPA | |||
| Patients, n (%) | 7 (58) | 2 (29) | .074 |
| Doses of BPA, median (range) | 38 (1-242) | 24.5 (19-30) | |
| Doses per patients | 43.4 | 7 | |
| Time from diagnosis to BPA initiation, median (range), d | 9 (0-35) | 0 (0-0) | .047 |
| RBC transfusions | |||
| Patients, n (%) | 11 (92) | 2 (29) | .010 |
| Units of RBC, median (range), doses | 22 (2-82) | 14 (10-18) | |
| Units per patients | 26.7 | 4 | |
| Invasive procedure | |||
| Patients, n (%) | 5 (42) | 1 (14) | .333 |
| Colonoscopy | |||
| Patients, n (%) | 5 (42) | 1 (14) | |
| Events, n | 12 | 2 | |
| Interventional radiology | |||
| Patients, n (%) | 2 (17) | 0 (0) | |
| Events, n | 4 | 0 | |
| Surgical operation | |||
| Patients, n (%) | 1 (8) | 0 (0) | |
| Events, n | 1 | 0 | |
| Cystoscopy | |||
| Patients, n (%) | 1 (8) | 0 (0) | |
| Events, n | 1 | 0 | |
| Complications | |||
| Infection | |||
| Patients, n (%) | 7 (58) | 0 (0) | .017 |
| Events, n | 13 | 0 | |
| Thrombosis | |||
| Patients, n (%) | 0 (0) | 0 (0) | |
| Events, n | 0 | 0 | |
| Hospital stays, median (range), d | 73.5 (29-202) | 44 (15-83) | <.001 |
| Outcome, n (%) | |||
| Death | 8 (67) | 0 (0) | .013 |
| During hospitalization | 3 (25) | 0 (0) | |
| After discharge | 5 (42) | 0 (0) | |
| Bleeding | 3 (25) | 0 (0) | |
| Infection | 1 (8) | 0 (0) | |
| Discharge to home | 3 (25) | 7 (100) | .003 |
| Transfer to another facilities | 6 (50) | 0 (0) | .044 |
CY, cyclophosphamide; CyA, cyclosporine A; PSL, prednisolone; RTX, rituximab.